METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted radiation shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a drug called 177Lu-PSMA-617 in 51 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug delivers a small dose of radiation directly to cancer cells to damage their DNA. The goal is to see if it can slow cancer grow…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
New combo aims to boost radiation's punch against hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can help treat metastatic castration-resistant prostate cancer that has stopped responding to other treatments. Abemaciclib may increase the number of targets (PSMA) on …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Triple-Drug attack aims to halt bone metastases in prostate cancer
Disease control Recruiting nowThis study tests whether adding two newer drugs (M3814 and avelumab) to the standard radioactive drug radium-223 can better control advanced prostate cancer that has spread to bones. About 90 men with castration-resistant prostate cancer will receive either radium-223 alone, radi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New pill takes on Hard-to-Treat prostate cancer by targeting a key enzyme and boosting immunity
Disease control Recruiting nowThis study tests a new daily pill, (R)-9bMS, for men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has stopped responding to standard hormone treatments. The drug works by blocking a protein called ACK1 and also helps the immune system fight the tumor.…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New imaging agent could sharpen view of prostate cancer spread
Diagnosis Recruiting nowThis study involves 30 men with advanced prostate cancer who are already scheduled for a standard treatment called 177Lu-PSMA therapy. Researchers want to see if a newer type of PET scan (18F-DCFPyL) can detect cancer spots as well as the current standard scan (68Ga-PSMA-11). The…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 17, 2026 05:46 UTC